Atenolol in hypertension: is it a wise choice? (Q33208768)

23 July 2017

0 references

Atenolol in hypertension: is it a wise choice? (English)

1 reference

23 July 2017

1 reference

Bo Carlberg

1

1 reference

23 July 2017

Ola Samuelsson

series ordinal

2

1 reference

23 July 2017

Lars Hjalmar Lindholm

series ordinal

3

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

23 July 2017

1 reference

23 July 2017

364

1 reference

23 July 2017

9446

1 reference

23 July 2017

1684-1689

1 reference

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

23 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

β-blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Might losartan reduce sudden cardiac death in diabetic patients with hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

beta Blockade after myocardial infarction: systematic review and meta regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Randomised trial of treatment of hypertension in elderly patients in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917355-8

7 January 2021

10.1016/S0140-6736(04)17355-8

Identifiers

DOI

1 reference

23 July 2017

1 reference